Interviews

Discover how rectal spacers revolutionize prostate cancer treatment by reducing side effects and enhancing radiation dose delivery for better patient outcomes.

Amer Zeidan, MBBS, discusses common adverse events and toxicity management for imetelstat in patients with myelodysplastic syndromes.

Discover how NBTXR3 enhances radiation therapy for head and neck cancer, boosting treatment efficacy while protecting healthy tissue.

Recent analysis reveals that rectal spacers significantly lower recurrence rates in prostate cancer patients undergoing radiation therapy, enhancing treatment outcomes.

Dr. Colette Shen discusses unmet needs in recurrent head and neck cancer, highlighting a novel treatment study aimed at improving patient outcomes.

A new study reveals a groundbreaking treatment for newly diagnosed multiple myeloma, achieving 100% response rates and minimal residual disease negativity.

FDA's new guidance clarifies overall survival data collection in clinical trials, emphasizing long-term follow-up, subgroup analysis, and trial design considerations.

Dr Harpreet Singh explores the FDA's new guidance on overall survival as a clinical trial endpoint, addressing its implications and challenges in oncology.

A groundbreaking study reveals the potential of alternative donors in bone marrow transplantation, paving the way for improved patient outcomes and innovative practices.

Innovative research transforms bone marrow transplantation, enhancing outcomes with mismatched and haploidentical donors, expanding access to life-saving treatments.

A new study reveals that optimized donor search algorithms significantly enhance transplant outcomes for patients, even with alternative donor sources.

Innovative NBTXR3 shows promise in enhancing radiotherapy for recurrent head and neck cancer, potentially transforming treatment options for patients.

A new study explores strategies to enhance survival rates for patients facing challenges in finding bone marrow donors, advocating for quicker alternative options.

Discover key advancements in breast cancer treatment and the ongoing challenges in access, drug resistance, and patient quality of life.

Experts emphasize the need for regulatory alignment between the FDA and EMA to streamline radiopharmaceutical development and enhance patient access.

Lowell B. Anthony, MD, discusses the potential benefits of cabozantinib for patients for different types of patients with neuroendocrine tumors.

Discover groundbreaking advancements in breast cancer treatment, focusing on targeted therapies, immunotherapy, and personalized care strategies for improved patient outcomes.

Dr. Shane Dormady shares innovative cancer treatment strategies, emphasizing hope and precision medicine to empower young adult patients facing diagnoses.

Sarah Premji, MD, discusses recent advancements in the breast cancer treatment landscape.

Julie Brahmer, MD, and David P. Carbone, MD, PhD, share insights on managing toxicities of immune checkpoint inhibitor therapies in non–small cell lung cancer.

Dr Harpreet Singh discusses the FDA's new guidance on radiopharmaceutical dosing, emphasizing dose justification and data integration for patient safety.

Dr Harpreet Singh discusses the FDA's draft guidance on radiopharmaceutical dosing, highlighting significant shifts in dose limits and safety monitoring for clinical trials.

Harpreet Singh, MD, former FDA director, discusses the FDA's new draft guidance on radiopharmaceutical dosing and its relation to Project Optimus.

Innovative advancements in cell therapy enhance NK cells for solid tumors, aiming for effective treatments while prioritizing patient safety and clinical success.

Discover how El Camino Health's multidisciplinary approach enhances cancer care for younger adults, featuring collaboration among diverse medical specialists.

Gerrina Ruiter, MD, PhD, highlights the Beamion LUNG-1 study's impact on treating HER2-mutant non-small cell lung cancer with brain metastases.

Katy Rezvani, MD, PhD, discusses advancements in CAR-NK cell therapy, focusing on enhancing antitumor efficacy while ensuring safety through precise gene editing techniques.

Dr Sarah Premji discusses advancements in breast cancer treatment, emphasizing community trials, personalized therapies, and how to address unmet patient needs.

Dr Katy Rezvani reveals groundbreaking insights on enhancing CAR-NK cell therapy's effectiveness against solid tumors through innovative genetic strategies.

Katy Rezvani, MD, PhD, explores innovative CAR-NK cell therapies, highlighting their potential to overcome challenges in treating solid tumors and enhancing cancer treatment efficacy.